European Patent Office Cancels Oral Opposition Proceedings Concerning Cantargia's Patent for Hematological Cancers

STOCKHOLM, Jan. 22, 2018 /PRNewswire/ --In the ongoing opposition proceedings at the European Patent Office ("EPO") concerning Cantargia AB's ("Cantargia") patent for antibody treatment against IL1RAP in hematological cancers, EPO has informed the company that the oral proceedings that...

from PR Newswire: //http://ift.tt/2DBGu8T